IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 67.706
EU - Europa 3.284
AS - Asia 1.308
Continente sconosciuto - Info sul continente non disponibili 25
SA - Sud America 23
OC - Oceania 19
AF - Africa 13
Totale 72.378
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 67.676
IE - Irlanda 767
CN - Cina 688
UA - Ucraina 668
IT - Italia 642
KR - Corea 490
DE - Germania 443
GB - Regno Unito 226
FI - Finlandia 181
FR - Francia 130
SE - Svezia 69
PL - Polonia 47
IN - India 40
RU - Federazione Russa 32
CA - Canada 29
EU - Europa 19
JP - Giappone 19
AU - Australia 18
BE - Belgio 16
NL - Olanda 16
HK - Hong Kong 14
SG - Singapore 12
BR - Brasile 10
ES - Italia 10
IR - Iran 10
EG - Egitto 7
VN - Vietnam 7
CH - Svizzera 5
PE - Perù 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CO - Colombia 4
HU - Ungheria 4
RO - Romania 4
AL - Albania 3
AR - Argentina 3
AT - Austria 3
BD - Bangladesh 3
GR - Grecia 3
ID - Indonesia 3
MK - Macedonia 3
PK - Pakistan 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
IL - Israele 2
KZ - Kazakistan 2
MA - Marocco 2
NO - Norvegia 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TR - Turchia 2
TW - Taiwan 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
CZ - Repubblica Ceca 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
SD - Sudan 1
Totale 72.378
Salva come PNG Salva come JPEG
Città #
Houston 22.108
Woodbridge 18.291
Wilmington 16.089
Fairfield 2.307
Ann Arbor 1.484
Ashburn 1.045
Seattle 897
Cambridge 834
Chandler 827
Dublin 704
Jacksonville 588
Dearborn 574
Medford 528
Beijing 272
Rome 269
Lawrence 253
New York 230
Hangzhou 131
San Diego 116
Menlo Park 102
Milan 70
London 65
Creede 52
Center 51
Norwalk 41
Seoul 40
Kraków 39
Engelhard 34
Zhengzhou 32
Nanjing 30
Hefei 29
Mountain View 28
Shanghai 28
Hackensack 26
Redwood City 24
Chicago 22
Guangzhou 21
Helsinki 21
Verona 21
Detroit 18
Kunming 18
Toronto 18
Pune 17
Monte Vista 15
Brussels 13
Florence 13
Nanchang 13
Kilburn 12
Indiana 10
Jinan 10
Billings 9
Boardman 9
Bologna 9
Fuzhou 9
Washington 9
Marseille 8
Redmond 8
Saint Petersburg 8
Council Bluffs 7
Hong Kong 7
Mülheim 7
Tokyo 7
Torre Del Greco 7
Brescia 6
Dong Ket 6
Los Angeles 6
New Bedfont 6
Phoenix 6
San Francisco 6
Changsha 5
Chiswick 5
Falls Church 5
Frankfurt am Main 5
Hebei 5
Hounslow 5
Lappeenranta 5
Lima 5
Madrid 5
Shenyang 5
Simi Valley 5
Taiyuan 5
Victoria 5
Wuhan 5
Budapest 4
Chennai 4
La Veta 4
Ladenburg 4
Palo Alto 4
Paris 4
San Jose 4
Siena 4
São Paulo 4
Urbana 4
Xian 4
Acton 3
Albano Laziale 3
Andong 3
Arezzo 3
Bari 3
Central 3
Totale 68.752
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.333
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.616
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.575
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.224
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.154
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 465
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 464
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 429
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 421
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 416
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 415
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 414
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 413
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 410
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 409
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 409
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 405
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 403
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 399
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 398
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 397
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 396
Panobinostat for the treatment of acute myelogenous leukemia 394
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 392
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 391
Clonal evolution in therapy-related neoplasms 391
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 390
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 390
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 388
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 387
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 387
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 386
Therapy related leukemias: susceptibility, prevention and treatment 386
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 385
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 384
Small lymphocytic lymphoma in a patient with Fabry disease 383
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 383
Mobilization and selection of CD34+ cells 382
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 381
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 380
New treatments for myelodysplastic syndromes 380
Prevalence of obesity in young adults with acute lymphoblastic leukemia 379
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 379
Hepato-splenic mycotic abscesses in patients with acute leukemia 379
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 379
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 378
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 378
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 378
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 378
Epigenetic changes in therapy-related MDS/AML 376
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 376
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 376
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 375
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 374
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 371
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 371
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 369
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 368
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 367
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 367
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 366
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 366
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 366
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 365
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 365
Why methylation is not a marker predictive of response to hypomethylating agents 364
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 364
Incidence and susceptibility to therapy-related myeloid neoplasms 363
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 363
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 363
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 362
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 361
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 360
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 360
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 360
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 359
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 358
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 357
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 357
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 357
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 357
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 353
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 353
Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker 353
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 351
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 350
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 350
Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan 349
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 349
Outcome of therapy-related myeloid neoplasms treated with azacitidine 349
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 348
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 348
Fanconi anemia gene variants in therapy-related myeloid neoplasms 348
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 347
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 347
Inhibition of hematopoiesis by competitive binding of transcription factor PU.1 345
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 344
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 344
Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms 343
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 342
Totale 43.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.130
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.130
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195.541 0 0 0 0 0 0 0 0 0 1.767 1.996 1.778
2019/202018.961 1.829 1.327 1.222 1.891 1.671 2.018 1.801 1.779 1.832 1.422 1.096 1.073
2020/202110.816 1.263 1.138 1.160 1.230 1.378 1.094 1.365 1.083 285 266 447 107
2021/20222.502 118 293 127 61 78 209 129 149 178 144 268 748
2022/20232.777 340 176 135 272 182 699 486 120 208 20 77 62
2023/20241.031 127 38 149 56 125 347 67 33 51 38 0 0
Totale 73.551